ANP_PHARMA_LTD - Accounts

Company Registration No. 06111337 (England and Wales)
ANP PHARMA LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2019
PAGES FOR FILING WITH REGISTRAR
ANP PHARMA LTD
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 8
ANP PHARMA LTD
BALANCE SHEET
AS AT
31 MARCH 2019
31 March 2019
- 1 -
2019
2018
Notes
£
£
£
£
Fixed assets
Intangible assets
3
74,418
148,836
Tangible assets
4
200,440
103,294
Investments
5
-
1
274,858
252,131
Current assets
Stocks
106,807
139,411
Debtors
6
506,007
608,927
Cash at bank and in hand
281,936
319,699
894,750
1,068,037
Creditors: amounts falling due within one year
7
(688,365)
(399,167)
Net current assets
206,385
668,870
Total assets less current liabilities
481,243
921,001
Creditors: amounts falling due after more than one year
8
-
(29,981)
Provisions for liabilities
-
(14,945)
Net assets
481,243
876,075
Capital and reserves
Called up share capital
9
100
100
Profit and loss reserves
481,143
875,975
Total equity
481,243
876,075

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 March 2019 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

ANP PHARMA LTD
BALANCE SHEET (CONTINUED)
AS AT
31 MARCH 2019
31 March 2019
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 10 June 2020 and are signed on its behalf by:
A Patel
Director
Company Registration No. 06111337
ANP PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2019
- 3 -
1
Accounting policies
Company information

ANP Pharma Ltd is a private company limited by shares incorporated in England and Wales. The registered office is Unit 9 Honywood Business Park, Honywood Road, Basildon, Essex, England, SS14 3HW.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

As stated in note 13, the director has considered the effect of the Covid-19 outbreak. The director consider that the outbreak is unlikely to cause a significant disruption to the company’s business and is confident that the company can continue as a going concern for a period of at least twelve months from the date of approval of these financial statements. The director has a reasonable expectation that the company has adequate resources to continue in operation for the foreseeable future.true

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods provided in the normal course of business, and is shown net of VAT. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.4
Intangible fixed assets - goodwill

Acquired goodwill is written off over a period of fifteen years.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold improvements
Fixtures, fittings & equipment
25% reducing balance method
Motor vehicles
25% reducing balance method

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

ANP PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2019
1
Accounting policies
(Continued)
- 4 -
1.6
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

1.7
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

1.8
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises of direct materials only.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of replacement cost and cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.9
Cash at bank and in hand

Cash at bank and in hand are basic financial assets and include cash in hand and deposits held at call with banks.

1.10
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

ANP PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2019
1
Accounting policies
(Continued)
- 5 -
Basic financial liabilities

Basic financial liabilities, including trade creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.11
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs.

1.12
Taxation

The tax expense represents the sum of the tax currently payable.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

1.13
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

1.14
Retirement benefits

The company operates a defined contribution scheme for the benefit of its employees. Contributions payable are charged to the profit and loss account in the year they are payable.

1.15
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to income on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease asset are consumed.

1.16
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation are included in the profit and loss account for the period.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was 7 (2018 - 8).

ANP PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2019
- 6 -
3
Intangible fixed assets
Goodwill
£
Cost
At 1 April 2018 and 31 March 2019
470,000
Amortisation and impairment
At 1 April 2018
321,164
Amortisation charged for the year
74,418
At 31 March 2019
395,582
Carrying amount
At 31 March 2019
74,418
At 31 March 2018
148,836
4
Tangible fixed assets
Leasehold improvements
Fixtures, fittings & equipment
Motor vehicles
Total
£
£
£
£
Cost
At 1 April 2018
-
249,829
-
249,829
Additions
55,401
51,733
40,000
147,134
At 31 March 2019
55,401
301,562
40,000
396,963
Depreciation and impairment
At 1 April 2018
-
146,535
-
146,535
Depreciation charged in the year
1,231
38,757
10,000
49,988
At 31 March 2019
1,231
185,292
10,000
196,523
Carrying amount
At 31 March 2019
54,170
116,270
30,000
200,440
At 31 March 2018
-
103,294
-
103,294
5
Fixed asset investments
2019
2018
£
£
Investments
-
1
ANP PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2019
5
Fixed asset investments
(Continued)
- 7 -
Movements in fixed asset investments
Shares in group undertakings and participating interests
£
Cost or valuation
At 1 April 2018
1
Valuation changes
(1)
At 31 March 2019
-
Carrying amount
At 31 March 2019
-
At 31 March 2018
1
6
Debtors
2019
2018
Amounts falling due within one year:
£
£
Trade debtors
346,848
517,912
Other debtors
132,219
89,669
Prepayments and accrued income
11,232
1,346
490,299
608,927
Deferred tax asset (note )
15,708
-
506,007
608,927
7
Creditors: amounts falling due within one year
2019
2018
Notes
£
£
Bank loans and overdrafts
-
3,384
Trade creditors
611,275
108,144
Corporation tax
-
70,700
Other taxation and social security
155
59
Other creditors
68,935
212,380
Accruals and deferred income
8,000
4,500
688,365
399,167
ANP PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2019
- 8 -
8
Creditors: amounts falling due after more than one year
2019
2018
Notes
£
£
Bank loans and overdrafts
-
29,981
9
Called up share capital
2019
2018
£
£
Ordinary share capital
Issued and fully paid
75 Ordinary A shares of £1 each
75
75
25 Ordinary B shares of £1 each
25
25
100
100
10
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2019
2018
£
£
557,333
66,500
11
Financial commitments, guarantees and contingent liabilities

The company has given a fixed and floating charge over the company’s assets to Lloyds Bank PLC, who have given a mortgage to ANP Property Investments Ltd for the purchase of a property. The directors A and D Patel are the directors and shareholders of ANP Property Investments Ltd.

12
Events after the reporting date

The director has considered the effect of the Covid-19 outbreak, that has been spreading throughout the world in early 2020, on the company’s activities.

 

This outbreak is unlikely to cause a disruption to the company’s business but at the date of approval of these financial statements, the extent and quantum of the disruption remains uncertain.

13
Related party transactions

At the year end, the company was owed £7,401 (2018: £166,624) by the director of the company.

2019-03-312018-04-01false11 June 2020CCH SoftwareCCH Accounts Production 2020.100No description of principal activityC CurranA PatelD R PatelS Patel061113372018-04-012019-03-31061113372019-03-3106111337core:Goodwill2019-03-3106111337core:Goodwill2018-03-31061113372017-04-012018-03-31061113372018-03-3106111337core:LeaseholdImprovements2019-03-3106111337core:FurnitureFittings2019-03-3106111337core:MotorVehicles2019-03-3106111337core:FurnitureFittings2018-03-3106111337core:CurrentFinancialInstrumentscore:WithinOneYear2019-03-3106111337core:CurrentFinancialInstrumentscore:WithinOneYear2018-03-3106111337core:CurrentFinancialInstruments2019-03-3106111337core:CurrentFinancialInstruments2018-03-3106111337core:Non-currentFinancialInstruments2018-03-3106111337core:ShareCapital2019-03-3106111337core:ShareCapital2018-03-3106111337core:RetainedEarningsAccumulatedLosses2019-03-3106111337core:RetainedEarningsAccumulatedLosses2018-03-3106111337core:ShareCapitalOrdinaryShares2019-03-3106111337core:ShareCapitalOrdinaryShares2018-03-3106111337bus:Director22018-04-012019-03-3106111337core:Goodwill2018-04-012019-03-3106111337core:FurnitureFittings2018-04-012019-03-3106111337core:MotorVehicles2018-04-012019-03-3106111337core:Goodwill2018-03-3106111337core:FurnitureFittings2018-03-31061113372018-03-3106111337core:LeaseholdImprovements2018-04-012019-03-3106111337bus:OrdinaryShareClass12019-03-3106111337bus:OrdinaryShareClass22019-03-3106111337bus:OrdinaryShareClass12018-04-012019-03-3106111337bus:OrdinaryShareClass22018-04-012019-03-3106111337bus:PrivateLimitedCompanyLtd2018-04-012019-03-3106111337bus:SmallCompaniesRegimeForAccounts2018-04-012019-03-3106111337bus:FRS1022018-04-012019-03-3106111337bus:AuditExemptWithAccountantsReport2018-04-012019-03-3106111337bus:Director12018-04-012019-03-3106111337bus:Director32018-04-012019-03-3106111337bus:CompanySecretary12018-04-012019-03-3106111337bus:FullAccounts2018-04-012019-03-31xbrli:purexbrli:sharesiso4217:GBP